Younger adults with newly diagnosed multiple myeloma who receive an autologous stem cell transplant (auto-HCT) have a median progression-free survival (PFS) of approximately 3.5 years and a median overall survival (OS) of ...
Jul 27, 2023
0
23
The PrE0505 phase 2 clinical trial results are published in the November 8 issue of Nature Medicine. The study evaluated the addition of durvalumab immunotherapy to standard chemotherapy in patients with previously untreated, ...
Nov 8, 2021
0
1
Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong ...
May 9, 2024
0
0
The U.S. Food and Drug Administration approved the combination of tremelimumab (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing ...
Nov 16, 2022
0
47
A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall ...
May 24, 2024
0
2
The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 ...
Apr 17, 2023
0
75
For patients with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma, pembrolizumab improves progression-free survival when combined with chemotherapy and trastuzumab, according to a study published online Oct. ...
Oct 25, 2023
0
1
Patients with acute myeloid leukemia (AML) who received vitamin C and D supplements while undergoing intensive chemotherapy had lower rates of complications, such as infections, bleeding, and inflammation, when compared with ...
Sep 6, 2023
0
2
(HealthDay)—Many older patients with acute myeloid leukemia (AML) do not receive any active treatment, and they have worse survival than those receiving active treatment, according to a study published online Sept. 4 in ...
Sep 18, 2019
0
1
New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and oesophageal cancers who currently have poor survival.
Sep 21, 2020
0
4
